T-cell receptor recognizing HIV-1 Gag-Pol antigens (Gag-Pol TCR)

T-cell receptors (TCRs) recognizing HIV-1 Gag-Pol antigens are critical components of the adaptive immune system's effort to control HIV-1 infection. These receptors, primarily found on CD8+ cytotoxic T lymphocytes and CD4+ helper T cells, identify specific viral peptides—such as the immunodominant SL9 epitope—presented by Human Leukocyte Antigen (HLA) molecules on the surface of infected cells (1.3.2, 1.5.2). Because Gag and Pol are highly conserved structural and enzymatic polyproteins essential for the viral life cycle, they are primary targets for natural immune control, particularly in 'Elite Controllers' who maintain low viral loads without medication (1.1.2, 1.5.1). In therapeutic development, these receptors are targeted through adoptive cell therapies (TCR-T), where patient T cells are engineered to express high-affinity TCRs, or through bispecific molecules like IMC-M113V that redirect T cells to eliminate the latent HIV reservoir (1.3.1, 1.4.3). While these strategies show promise for achieving a functional cure, challenges remain regarding viral escape through rapid mutation and the requirement for specific HLA matches in treated patients (1.1.3, 1.5.2). Current research focuses on enhancing TCR affinity and polyfunctionality to overcome these barriers and provide durable viral suppression (1.3.2, 1.5.3).

Other names

HIV-1 Gag-Pol specific T-cell receptorGag-specific TCRPol-specific TCRAnti-HIV TCRHIV-specific immune receptorsGag-Pol specific CD8+ T-cell receptor

Recognition of HIV-1 Gag or Pol-derived peptides presented by Major Histocompatibility Complex (MHC) molecules on the surface of infected cells, leading to T-cell activation, secretion of proinflammatory cytokines (e.g., IFN-gamma, IL-2), and direct osmotic lysis of the target cell (1.3.2, 1.5.2).